Novel Imaging Model Helps Reveal New Therapeutic Target for Pancreatic Cancer

Antisense treatment in preclinical models shows effectiveness against deadly tumors —

Pancreatic ductal adenocarcinoma, the most common of pancreatic cancers, is extraordinarily lethal, with a 5-year survival rate of just 6 percent. Chemotherapy treatments are poorly effective, in part due to a high degree of drug-resistance to currently used regimens.

In a new study, published online June 6 in Nature, researchers at University of California San Diego School of Medicine and Moores Cancer Center, together with colleagues at Keio University, the University of Nebraska and Ionis Pharmaceuticals describe an innovative new model that not only allowed them to track drug resistance in vivo, but also revealed a new therapeutic target … Read the Full Story from the UC San Diego Newsroom


Tannishtha Reya, PhD, Professor of Medicine in the Division of Hematology-Oncology and Professor of Pharmacology, was co-principal investigator of the project.

Dr. Frederick D. Park

Dr. Frederick D. Park

Another Department of Medicine coauthor was Frederick D. Park, MD, PhD, Assistant Professor in the Division of Gastroenterology.